Institutional buying ahead of key Phase 3 trial

Prosight Management’s decision to buy about US$10 million of Nektar Therapeutics (NKTR) stock ahead of a pivotal Phase 3 rezpegaldesleukin trial has turned attention to how institutional investors are positioning around the company’s clinical pipeline and cash resources.

Despite Prosight’s purchase, Nektar’s share price has been under pressure in the near term, with the stock down 27.35% on a 30 day share price return and 9.52% on a 90 day share price return. However, its 1 year total shareholder return is very large and its 3 year total shareholder return is also very large, which points to strong longer term momentum that contrasts with recent volatility and routine insider sales to cover tax obligations.

If you are weighing Nektar against other biotech ideas, it can be useful to see how the market is pricing AI driven healthcare opportunities through the Simply Wall St screener for 34 healthcare AI stocks

With the stock pulling back in the short term but delivering very large longer term returns and trading below the average analyst price target, the key question is whether Nektar is still mispriced or if markets are already fully pricing in future growth.

Most Popular Narrative: 54% Undervalued

Analysts following Nektar see a fair value of $144.25 per share versus the last close at $66.61. This sets up a wide gap between market pricing and the narrative view, which is built on rezpegaldesleukin and the broader autoimmune pipeline.

Advancing innovative therapies like REZPEG in large, underserved markets could drive substantial revenue growth and improve long-term financial performance.

Strong cash reserves and accelerated regulatory paths enable operational stability, support pipeline expansion, and reduce near-term financial risks.

Want to see what is baked into that fair value gap? The narrative leans on ambitious revenue trajectories, margin expansion and a future earnings multiple usually reserved for high growth leaders. Curious which specific assumptions try to justify that price target and how they fit together in the model? Read on and test whether those projections line up with your own view of Nektar's future.

Result: Fair Value of $144.25 (UNDERVALUED)

However, the story also carries real execution risk, with Nektar still loss making, heavily reliant on rezpegaldesleukin, and exposed to potential setbacks in late stage trials.

Another Angle On Valuation

The narrative points to a fair value of $144.25 per share, yet the current P/S ratio of 40.4x is far higher than the US Pharmaceuticals industry at 5.4x, the peer average at 9.3x, and even the fair ratio of 18.1x. Is the market overpaying for future potential or underestimating long term risk?

Next Steps

With sentiment clearly split between long term promise and real clinical and financial risks, it pays to move quickly and test the data yourself before opinions harden. Then weigh both sides of the story with our breakdown of 1 key reward and 3 important warning signs

Looking for more investment ideas?

If you stop with just one stock, you might miss opportunities that fit your style far better, so keep scanning the market and let the data work for you.

• Pinpoint potential bargains quickly by reviewing companies highlighted in the 49 high quality undervalued stocks.
• Prioritise resilience by checking stocks featured in the 67 resilient stocks with low risk scores.
• Target steady income potential by assessing companies in the 10 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.